Overview and Scope
Respiratory disease testing refers to the treatment process of testing for various respiratory diseases using physical examinations. It helps diagnose the lung condition and measures how fast it can blow air out, so the test’s results can assist a clinician in diagnosing respiratory disease even before a patient experience symptom.
Sizing and Forecast
The respiratory disease testing market size has grown steadily in recent years. It will grow from $3.42 billion in 2023 to $3.58 billion in 2024 at a compound annual growth rate (CAGR) of 4.6%. The growth in the historic period can be attributed to environmental factors and pollution, tobacco smoking epidemic, occupational respiratory hazards, awareness and health education programs, government initiatives for disease control.
The respiratory disease testing market size is expected to see steady growth in the next few years. It will grow to $4.31 billion in 2028 at a compound annual growth rate (CAGR) of 4.8%. The growth in the forecast period can be attributed to rise in airborne respiratory viruses, focus on home-based testing solutions, increased research in precision medicine, continued environmental health concerns, focus on early intervention and prevention. Major trends in the forecast period include point-of-care testing, integration of artificial intelligence (ai), remote monitoring technologies, telehealth services, customized biomarker panels, enhanced breath analysis techniques.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/respiratory-disease-testing-global-market-report
Segmentation & Regional Insights
The respiratory disease testing market covered in this report is segmented –
1) By Test Type: Imaging Tests, Mechanical Tests, In-Vitro Diagnostic Tests
2) By Products: Lung Volume, Imaging, Spirometry, Peak Flow, Blood Gas, Other Products
3) By Application: Chronic Obstructive Pulmonary Disease, Lung Cancer, Asthma, Tuberculosis Female, Other Application
4) By End-User: Hospitals, Physician clinics, Clinical laboratories, Other End-User
North America was the largest region in the respiratory disease testing market in 2023. Asia-Pacific is expected to be the fastest growing region in the global respiratory disease testing market during the forecast period. The regions covered in the respiratory disease testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=10304&type=smp
Major Driver Impacting Market Growth
The rising prevalence of respiratory diseases will boost the respiratory disease testing market going forward. Respiratory diseases refer to medical conditions that affect the respiratory system, which includes the lungs, bronchi, trachea, larynx, pharynx, and nasal passages. Respiratory disease testing is primarily used for the early detection and diagnosis of respiratory conditions, which can lead to earlier treatment and management. This can help prevent the progression of the disease and is also essential for controlling the spread of infectious respiratory diseases and reducing the risk of complications. For instance, in September 2022, according to the data from the NCD Alliance, a Switzerland-based civil society organization, lung cancer was the leading cause of cancer deaths worldwide, with 2.2 million new cases and 1.8 million fatalities anticipated year on year. Further, chronic respiratory disorders impacted 550 million adults globally, and 4.2 million people died, or 7 %. Therefore, the rising prevalence of respiratory diseases will drive the respiratory disease testing market forward
Key Industry Players
Major companies operating in the respiratory disease testing market report are Medtronic PLC, Carestream Medical Ltd., Abbott Laboratories, Siemens Healthineers AG, Koninklijke Philips N.V., ResMed Inc., Thermo Fisher Scientific Inc., Beckton Dickinson And Company, F. Hoffmann-La Roche Ltd., Nihon Kohden Corporation, GE HealthCare Technologies Inc., Merck And Co. Inc., Fisher And Paykel Healthcare Corporation Limited, Qiagen N.V., Medical Graphics Corporation, COSMED srl, ndd Medizintechnik AG, Vitalograph Ltd., MGC Diagnostics Corporation, Vyaire Medical Inc., Smiths Medical International Ltd., Masimo Corporation, Hamilton Medical AG, Drägerwerk AG & Co. KGaA, Hill-Rom Holdings Inc., OSI Systems Inc., Schiller AG, Baxter International Inc., Nonin Medical Inc., Viasys Healthcare Inc., Natus Medical Incorporated
The respiratory disease testing market report table of contents includes:
1. Executive Summary
2. Respiratory Disease Testing Market Characteristics
3. Respiratory Disease Testing Market Trends And Strategies
4. Respiratory Disease Testing Market – Macro Economic Scenario
5. Global Respiratory Disease Testing Market Size and Growth
.
.
.
31. Global Respiratory Disease Testing Market Competitive Benchmarking
32. Global Respiratory Disease Testing Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Respiratory Disease Testing Market
34. Respiratory Disease Testing Market Future Outlook and Potential Analysis
35. Appendix
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
